Impact of Baduanjin Qigong Exercise on Fatigue in Patients With NSCLC Undergoing Adjuvant Chemotherapy
2021年12月3日 更新者:Yu Qian、Hubei Cancer Hospital
Impact of Baduanjin Qigong Exercise on Fatigue in Patients With Non Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy: A Randomized Controlled Trial
Baduanjin,a type of Qigong which belongs to aerobic exercise, is very popular in China.
There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
In college students, it may enhance cardio respiratory function, lower limb function, and flexibility compared with usual exercise.
However, there is no previous relevant randomized controlled trials on the health promoting effects of Baduanjin exercise in targeted fatigued lung cancer patients.
Lung cancer survivors can experience fatigue due to multiple reasons that can strongly impact their quality of life throughout the remainder of their life.
Therefore, this randomized controlled trial in China was designed to assess the health promoting effects of Baduanjin exercise in fatigued lung cancer patients with the expectation of improvement in physical and psychological health.
研究概览
研究类型
介入性
注册 (预期的)
100
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Yu Qian, Dr
- 电话号码:+862787670255
- 邮箱:173653835@qq.com
学习地点
-
-
Hubei
-
Wuhan、Hubei、中国、430000
- 招聘中
- Hubei Cancer Hospital
-
接触:
- Yuan Wu, Dr.
- 电话号码:027-87670318
- 邮箱:gwgfe@163.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- This trial aims to enroll 18- to 75-year-old patients expected to survive > 3 months and with a Zubrod performance status of 0 to 2. All patients must have diagnosed as lung cancer and have at least one cycle of adjuvant chemotherapy. Enrolled patients should have a minimal ESAS fatigue as 3. Other inclusion criteria are lack of leptomeningeal disease, adequate hepatorenal function and blood counts (red blood cells, >3.0 * 1012/L; white blood cells, > 3.5 * 109/L; absolute neutrophil count, > 1.5 * 109/L; platelets, > 100 * 109/L; hemoglobin > 90 g/L).
Exclusion Criteria:
- Children
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention group
Participants in the intervention group received two months of Baduanjin exercise training provided by the specialist coach 3 days per week in Hubei Cancer Hospital, and they were also required to do Baduanjin exercise at home for the remaining 4 days each week for at least 20 min per day.
All the participants are requested to monitor and record adverse effects during their exercise sessions.
|
Baduanjin is very popular in China.
There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
|
|
安慰剂比较:Control group
Participants in the control group were requested to maintain their original daily physical activity for no less than 20 min per day over the following 6-month period and record their daily activity at home by themselves.
These data were collected by a researcher during the participants' time in the study and at the 6-month follow-up at the hospital.
After the 6-month follow-up, the participants were provided with 1-month professional Baduanjin exercise guidance by the trial's specialist coach for free if they wished.
|
Baduanjin is very popular in China.
There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Scale of fatigue
大体时间:6 months
|
6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Yuan Wu、Huazhong University of Science and Technology
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (预期的)
2021年12月1日
初级完成 (预期的)
2022年8月1日
研究完成 (预期的)
2023年8月1日
研究注册日期
首次提交
2021年12月1日
首先提交符合 QC 标准的
2021年12月3日
首次发布 (实际的)
2021年12月16日
研究记录更新
最后更新发布 (实际的)
2021年12月16日
上次提交的符合 QC 标准的更新
2021年12月3日
最后验证
2021年12月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- LLHBCH2021YN-029
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.